Recent Company News

• 07:03 AM ET Aug 14, 2026
  

  Adlai Nortye reports Q2 EPS ($0.04) vs year-ago ($0.19) ($12.86, 0.00)

• 07:09 AM ET Aug 03, 2026
  

  Adlai Nortye announces clinical trial notification submission and HREC approval for the phase I clinical trial of Pan-RAS(ON) inhibitor ADC AN4035 in Australia ($13.00, 0.00)

• 07:02 AM ET Jul 16, 2026
  

  Adlai Nortye announces first patient dosed in intermittent weekly dosing arm of global phase 1 trial of AN9025 ($10.63, 0.00)

• 05:17 PM ET May 28, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:39 AM ET May 28, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:17 AM ET Jun 22, 2026
  

  Adlai Nortye initiated overweight at Cantor Fitzgerald ($10.10, 0.00)

• 06:06 AM ET May 29, 2026
  

  BeOne Medicines presents BRUKINSA 78-month data at ASCO 2026 ($290.58, 0.00)

• 08:18 AM ET May 28, 2026
  

  CORRECTION: Adlai Nortye initiated at Oppenheimer with target of $32 ($11.00, 0.00)